{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:07:10Z","timestamp":1791288430412,"version":"4.3.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"DOI":"10.1007\/s12031-024-02297-1","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T20:21:32Z","timestamp":1733775692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advanced Glycation End Products in Neurodegenerative Diseases"],"prefix":"10.1007","volume":"74","author":[{"given":"Cibin T.","family":"Raghavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2297_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00018-015-2091-z","volume":"73","author":"C Adamopoulos","year":"2016","unstructured":"Adamopoulos C, Piperi C, Gargalionis AN, Dalagiorgou G, Spilioti E, Korkolopoulou P, Diamanti-Kandarakis E, Papavassiliou AG (2016) Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1\/2\u2013NF-\u03baB and JNK\u2013AP-1 signaling pathways. Cell Mol Life Sci 73:1685\u20131698. https:\/\/doi.org\/10.1007\/s00018-015-2091-z","journal-title":"Cell Mol Life Sci"},{"key":"2297_CR2","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1021\/acschemneuro.7b00410","volume":"9","author":"K Batkulwar","year":"2018","unstructured":"Batkulwar K, Godbole R, Banarjee R, Kassaar O, Williams RJ, Kulkarni MJ (2018) Advanced glycation end products modulate amyloidogenic APP processing and tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer\u2019s disease. ACS Chem Neurosci 9:988\u20131000. https:\/\/doi.org\/10.1021\/acschemneuro.7b00410","journal-title":"ACS Chem Neurosci"},{"key":"2297_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fnins.2019.01399","volume":"13","author":"LD Bernal-Conde","year":"2019","unstructured":"Bernal-Conde LD, Ramos-Acevedo R, Reyes-Hern\u00e1ndez MA, Balbuena-Olvera AJ, Morales-Moreno ID, Arg\u00fcero-S\u00e1nchez R, Sch\u00fcle B, Guerra-Crespo M (2019) Alpha-synuclein physiology and pathology: a perspective on cellular structures and organelles. Front Neurosci 13:1399. https:\/\/doi.org\/10.3389\/fnins.2019.01399","journal-title":"Front Neurosci"},{"key":"2297_CR4","doi-asserted-by":"publisher","first-page":"1155175","DOI":"10.3389\/fnmol.2023.1155175","volume":"16","author":"R Bhattacharya","year":"2023","unstructured":"Bhattacharya R, Alam MR, Kamal MA, Seo KJ, Singh LR (2023) AGE-RAGE axis culminates into multiple pathogenic processes: a central road to neurodegeneration. Front Mol Neurosci 16:1155175. https:\/\/doi.org\/10.3389\/fnmol.2023.1155175","journal-title":"Front Mol Neurosci"},{"key":"2297_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med Berl Ger 83:876\u2013886. https:\/\/doi.org\/10.1007\/s00109-005-0688-7","journal-title":"J Mol Med Berl Ger"},{"key":"2297_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/JHD-190366","volume":"8","author":"IC Br\u00e1s","year":"2019","unstructured":"Br\u00e1s IC, K\u00f6nig A, Outeiro TF (2019) Glycation in Huntington\u2019s disease: a possible modifier and target for intervention. J Huntingt Dis 8:245\u2013256. https:\/\/doi.org\/10.3233\/JHD-190366","journal-title":"J Huntingt Dis"},{"key":"2297_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT (2020) Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci 23:1183\u20131193. https:\/\/doi.org\/10.1038\/s41593-020-0687-6","journal-title":"Nat Neurosci"},{"key":"2297_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pharmthera.2017.02.030","volume":"177","author":"K Byun","year":"2017","unstructured":"Byun K, Yoo Y, Son M, Lee J, Jeong G-B, Park YM, Salekdeh GH, Lee B (2017) Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases. Pharmacol Ther 177:44\u201355. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.030","journal-title":"Pharmacol Ther"},{"key":"2297_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-180098","volume":"63","author":"Z Cai","year":"2018","unstructured":"Cai Z, Qiao P-F, Wan C-Q, Cai M, Zhou N-K, Li Q (2018) Role of blood-brain barrier in Alzheimer\u2019s disease. J Alzheimers Dis JAD 63:1223\u20131234. https:\/\/doi.org\/10.3233\/JAD-180098","journal-title":"J Alzheimers Dis JAD"},{"key":"2297_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0006-8993(96)00729-9","volume":"737","author":"R Castellani","year":"1996","unstructured":"Castellani R, Smith MA, Richey GL, Perry G (1996) Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737:195\u2013200. https:\/\/doi.org\/10.1016\/0006-8993(96)00729-9","journal-title":"Brain Res"},{"key":"2297_CR11","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00018-009-0058-7","volume":"66","author":"L Chen","year":"2009","unstructured":"Chen L, Wei Y, Wang X, He R (2009) D-Ribosylated tau forms globular aggregates with high cytotoxicity. Cell Mol Life Sci CMLS 66:2559\u20132571. https:\/\/doi.org\/10.1007\/s00018-009-0058-7","journal-title":"Cell Mol Life Sci CMLS"},{"key":"2297_CR12","doi-asserted-by":"publisher","first-page":"e9052","DOI":"10.1371\/journal.pone.0009052","volume":"5","author":"L Chen","year":"2010","unstructured":"Chen L, Wei Y, Wang X, He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS ONE 5:e9052. https:\/\/doi.org\/10.1371\/journal.pone.0009052","journal-title":"PLoS ONE"},{"key":"2297_CR13","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/01.jnen.0000179050.54522.5a","volume":"64","author":"E Dalf\u00f3","year":"2005","unstructured":"Dalf\u00f3 E, Portero-Ot\u00edn M, Ayala V, Mart\u00ednez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816\u2013830. https:\/\/doi.org\/10.1097\/01.jnen.0000179050.54522.5a","journal-title":"J Neuropathol Exp Neurol"},{"key":"2297_CR14","doi-asserted-by":"publisher","unstructured":"Derk J, MacLean M, Juranek J, Schmidt AM (2018) The receptor for advanced glycation endproducts (RAGE) and mediation of inflammatory neurodegeneration. J Alzheimer\u2019s Dis Park 8(1):421.\u00a0https:\/\/doi.org\/10.4172\/2161-0460.1000421","DOI":"10.4172\/2161-0460.1000421"},{"key":"2297_CR15","doi-asserted-by":"publisher","first-page":"104098","DOI":"10.1016\/j.mvr.2020.104098","volume":"133","author":"A Dobi","year":"2021","unstructured":"Dobi A, Rosanaly S, Devin A, Baret P, Meilhac O, Harry GJ, d\u2019Hellencourt CL, Rondeau P (2021) Advanced glycation end-products disrupt brain microvascular endothelial cell barrier: the role of mitochondria and oxidative stress. Microvasc Res 133:104098. https:\/\/doi.org\/10.1016\/j.mvr.2020.104098","journal-title":"Microvasc Res"},{"key":"2297_CR16","unstructured":"DSM, https:\/\/www.psychiatry.org:443\/psychiatrists\/practice\/dsm"},{"key":"2297_CR17","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/hmg\/ddy017","volume":"27","author":"F Fang","year":"2018","unstructured":"Fang F, Yu Q, Arancio O, Chen D, Gore SS, Yan SS, Yan SF (2018) RAGE mediates A\u03b2 accumulation in a mouse model of Alzheimer\u2019s disease via modulation of \u03b2- and \u03b3-secretase activity. Hum Mol Genet 27:1002\u20131014. https:\/\/doi.org\/10.1093\/hmg\/ddy017","journal-title":"Hum Mol Genet"},{"key":"2297_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2008.02.163","volume":"370","author":"A Galichet","year":"2008","unstructured":"Galichet A, Weibel M, Heizmann CW (2008) Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun 370:1\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2008.02.163","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2297_CR19","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/jnc.15890","volume":"168","author":"J Gasparotto","year":"2023","unstructured":"Gasparotto J, Somensi N, Girardi CS, Bittencourt RR, de Oliveira LM, Hoefel LP, Scheibel IM, Peixoto DO, Moreira JCF, Outeiro TF, Gelain DP (2023) Is it all the RAGE? Defining the role of the receptor for advanced glycation end products in Parkinson\u2019s disease. J Neurochem 168(8):1608\u201324. https:\/\/doi.org\/10.1111\/jnc.15890","journal-title":"J Neurochem"},{"key":"2297_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/glycob\/cwz073","volume":"30","author":"E Haque","year":"2019","unstructured":"Haque E, Kamil M, Hasan A, Irfan S, Sheikh S, Khatoon A, Nazir A, Mir SS (2019) Advanced glycation end products (AGEs), protein aggregation and their cross talk: new insight in tumorigenesis. Glycobiology 30:49\u201357. https:\/\/doi.org\/10.1093\/glycob\/cwz073","journal-title":"Glycobiology"},{"key":"2297_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0092-8674(00)80801-6","volume":"97","author":"MA Hofmann","year":"1999","unstructured":"Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM (1999) RAGE mediates a novel proinflammatory axis. Cell 97:889\u2013901. https:\/\/doi.org\/10.1016\/S0092-8674(00)80801-6","journal-title":"Cell"},{"key":"2297_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/10409238.2020.1819194","volume":"55","author":"N Jangde","year":"2020","unstructured":"Jangde N, Ray R, Rai V (2020) RAGE and its ligands: from pathogenesis to therapeutics. Crit Rev Biochem Mol Biol 55:555\u2013575. https:\/\/doi.org\/10.1080\/10409238.2020.1819194","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2297_CR23","doi-asserted-by":"publisher","first-page":"e78267","DOI":"10.1371\/journal.pone.0078267","volume":"8","author":"J Jules","year":"2013","unstructured":"Jules J, Maiguel D, Hudson BI (2013) Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLoS ONE 8:e78267. https:\/\/doi.org\/10.1371\/journal.pone.0078267","journal-title":"PLoS ONE"},{"key":"2297_CR24","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s12264-022-00878-x","volume":"38","author":"J Juranek","year":"2022","unstructured":"Juranek J, Mukherjee K, Kordas B, Za\u0142\u0119cki M, Korytko A, Zglejc-Waszak K, Szuszkiewicz J, Banach M (2022) Role of RAGE in the pathogenesis of neurological disorders. Neurosci Bull 38:1248\u20131262. https:\/\/doi.org\/10.1007\/s12264-022-00878-x","journal-title":"Neurosci Bull"},{"key":"2297_CR25","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.1002\/jcp.30324","volume":"236","author":"A Kamynina","year":"2021","unstructured":"Kamynina A, Esteras N, Koroev DO, Angelova PR, Volpina OM, Abramov AY (2021) Activation of RAGE leads to the release of glutamate from astrocytes and stimulates calcium signal in neurons. J Cell Physiol 236:6496\u20136506. https:\/\/doi.org\/10.1002\/jcp.30324","journal-title":"J Cell Physiol"},{"key":"2297_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/biom12040542","volume":"12","author":"M Khalid","year":"2022","unstructured":"Khalid M, Petroianu G, Adem A (2022) Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules 12:542. https:\/\/doi.org\/10.3390\/biom12040542","journal-title":"Biomolecules"},{"key":"2297_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.freeradbiomed.2010.05.005","volume":"49","author":"S-Y Ko","year":"2010","unstructured":"Ko S-Y, Lin Y-P, Lin Y-S, Chang S-S (2010) Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 49:474\u2013480. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.05.005","journal-title":"Free Radic Biol Med"},{"key":"2297_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/JPD-171285","volume":"8","author":"A K\u00f6nig","year":"2018","unstructured":"K\u00f6nig A, Vicente Miranda H, Outeiro TF (2018) Alpha-synuclein glycation and the action of anti-diabetic agents in Parkinson\u2019s disease. J Park Dis 8:33\u201343. https:\/\/doi.org\/10.3233\/JPD-171285","journal-title":"J Park Dis"},{"key":"2297_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5808\/GI.2013.11.4.224","volume":"11","author":"EJ Lee","year":"2013","unstructured":"Lee EJ, Park JH (2013) Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics Inform 11:224\u2013229. https:\/\/doi.org\/10.5808\/GI.2013.11.4.224","journal-title":"Genomics Inform"},{"key":"2297_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.02.018","volume":"317","author":"J Li","year":"2012","unstructured":"Li J, Liu D, Sun L, Lu Y, Zhang Z (2012) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci 317:1\u20135. https:\/\/doi.org\/10.1016\/j.jns.2012.02.018","journal-title":"J Neurol Sci"},{"key":"2297_CR31","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s13361-014-0996-7","volume":"25","author":"AF Lopez-Clavijo","year":"2014","unstructured":"Lopez-Clavijo AF, Duque-Daza CA, Soulby A, Canelon IR, Barrow M, O\u2019Connor PB (2014) Unexpected crosslinking and diglycation as advanced glycation end-products from glyoxal. J Am Soc Mass Spectrom 25:2125\u20132133. https:\/\/doi.org\/10.1007\/s13361-014-0996-7","journal-title":"J Am Soc Mass Spectrom"},{"key":"2297_CR32","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1046\/j.1432-1327.2000.01452.x","volume":"267","author":"C Loske","year":"2000","unstructured":"Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, M\u00fcnch G (2000) Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 267:4171\u20134178. https:\/\/doi.org\/10.1046\/j.1432-1327.2000.01452.x","journal-title":"Eur J Biochem"},{"key":"2297_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0891-0618(00)00096-X","volume":"20","author":"G M\u00fcnch","year":"2000","unstructured":"M\u00fcnch G, L\u00fcth HJ, Wong A, Arendt Th, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of \u03b1-synuclein by advanced glycation endproducts \u2014 an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20:253\u2013257. https:\/\/doi.org\/10.1016\/S0891-0618(00)00096-X","journal-title":"J Chem Neuroanat"},{"key":"2297_CR34","doi-asserted-by":"publisher","first-page":"S517","DOI":"10.3233\/JAD-179907","volume":"64","author":"RM Nisbet","year":"2018","unstructured":"Nisbet RM, G\u00f6tz J (2018) Amyloid-\u03b2 and tau in Alzheimer\u2019s disease: novel pathomechanisms and non-pharmacological treatment strategies. J Alzheimers Dis JAD 64:S517\u2013S527. https:\/\/doi.org\/10.3233\/JAD-179907","journal-title":"J Alzheimers Dis JAD"},{"key":"2297_CR35","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1523\/JNEUROSCI.0204-08.2008","volume":"28","author":"N Origlia","year":"2008","unstructured":"Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, Chen JX, Schmidt AM, Arancio O, Yan SD, Domenici L (2008) Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-\u03b2-mediated cortical synaptic dysfunction. J Neurosci 28:3521\u20133530. https:\/\/doi.org\/10.1523\/JNEUROSCI.0204-08.2008","journal-title":"J Neurosci"},{"key":"2297_CR36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1126\/science.1143780","volume":"317","author":"TF Outeiro","year":"2007","unstructured":"Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet J-C, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson\u2019s disease. Science 317:516\u2013519. https:\/\/doi.org\/10.1126\/science.1143780","journal-title":"Science"},{"key":"2297_CR37","volume-title":"Neurodegenerative diseases biomarkers: towards translating research to clinical practice","year":"2022","unstructured":"Peplow PV, Martinez B, Gennarelli TA (eds) (2022) Neurodegenerative diseases biomarkers: towards translating research to clinical practice. Springer, US, New York, NY"},{"key":"2297_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/1559827617708991","volume":"13","author":"C Prasad","year":"2019","unstructured":"Prasad C, Davis KE, Imrhan V, Juma S, Vijayagopal P (2019) Advanced glycation end products and risks for chronic diseases: intervening through lifestyle modification. Am J Lifestyle Med 13:384\u2013404. https:\/\/doi.org\/10.1177\/1559827617708991","journal-title":"Am J Lifestyle Med"},{"key":"2297_CR39","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1074\/jbc.M111.277731","volume":"287","author":"V Rai","year":"2012","unstructured":"Rai V, Maldonado AY, Burz DS, Reverdatto S, Schmidt AM, Shekhtman A (2012) Signal transduction in receptor for advanced glycation end products (RAGE). J Biol Chem 287:5133\u20135144. https:\/\/doi.org\/10.1074\/jbc.M111.277731","journal-title":"J Biol Chem"},{"key":"2297_CR40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.bbagen.2007.02.001","volume":"1770","author":"N Sattarahmady","year":"2007","unstructured":"Sattarahmady N, Moosavi-Movahedi AA, Ahmad F, Hakimelahi GH, Habibi-Rezaei M, Saboury AA, Sheibani N (2007) Formation of the molten globule-like state during prolonged glycation of human serum albumin. Biochim Biophys Acta 1770:933\u2013942. https:\/\/doi.org\/10.1016\/j.bbagen.2007.02.001","journal-title":"Biochim Biophys Acta"},{"key":"2297_CR41","doi-asserted-by":"publisher","first-page":"e86903","DOI":"10.1371\/journal.pone.0086903","volume":"9","author":"L Sessa","year":"2014","unstructured":"Sessa L, Gatti E, Zeni F, Antonelli A, Catucci A, Koch M, Pompilio G, Fritz G, Raucci A, Bianchi ME (2014) The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS ONE 9:e86903. https:\/\/doi.org\/10.1371\/journal.pone.0086903","journal-title":"PLoS ONE"},{"key":"2297_CR42","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/jnr.21644","volume":"86","author":"S Shaikh","year":"2008","unstructured":"Shaikh S, Nicholson LFB (2008) Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86:2071\u20132082. https:\/\/doi.org\/10.1002\/jnr.21644","journal-title":"J Neurosci Res"},{"key":"2297_CR43","doi-asserted-by":"publisher","first-page":"111750","DOI":"10.1016\/j.biopha.2021.111750","volume":"140","author":"Q Song","year":"2021","unstructured":"Song Q, Liu J, Dong L, Wang X, Zhang X (2021) Novel advances in inhibiting advanced glycation end product formation using natural compounds. Biomed Pharmacother Biomedecine Pharmacother 140:111750. https:\/\/doi.org\/10.1016\/j.biopha.2021.111750","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"2297_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/164_2020_391","volume":"264","author":"KC Sourris","year":"2021","unstructured":"Sourris KC, Watson A, Jandeleit-Dahm K (2021) Inhibitors of advanced glycation end product (AGE) formation and accumulation. Handb Exp Pharmacol 264:395\u2013423. https:\/\/doi.org\/10.1007\/164_2020_391","journal-title":"Handb Exp Pharmacol"},{"key":"2297_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.abb.2003.08.013","volume":"419","author":"PJ Thornalley","year":"2003","unstructured":"Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419:31\u201340. https:\/\/doi.org\/10.1016\/j.abb.2003.08.013","journal-title":"Arch Biochem Biophys"},{"key":"2297_CR46","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cells11081312","volume":"11","author":"A Twarda-Clapa","year":"2022","unstructured":"Twarda-Clapa A, Olczak A, Bia\u0142kowska AM, Kozio\u0142kiewicz M (2022) Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs. Cells 11:1312. https:\/\/doi.org\/10.3390\/cells11081312","journal-title":"Cells"},{"key":"2297_CR47","doi-asserted-by":"publisher","first-page":"36798","DOI":"10.1038\/srep36798","volume":"6","author":"H Vicente Miranda","year":"2016","unstructured":"Vicente Miranda H, Gomes MA, Branco-Santos J, Breda C, L\u00e1zaro DF, Lopes LV, Herrera F, Giorgini F, Outeiro TF (2016) Glycation potentiates neurodegeneration in models of Huntington\u2019s disease. Sci Rep 6:36798. https:\/\/doi.org\/10.1038\/srep36798","journal-title":"Sci Rep"},{"issue":"1399","key":"2297_CR48","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/brain\/awx056","volume":"140","author":"H Vicente Miranda","year":"2017","unstructured":"Vicente Miranda H, Szego \u00c9M, Oliveira LMA, Breda C, Darendelioglu E, de Oliveira RM, Ferreira DG, Gomes MA, Rott R, Oliveira M, Munari F, Enguita FJ, Sim\u00f5es T, Rodrigues EF, Heinrich M, Martins IC, Zamolo I, Riess O, Cordeiro C, Ponces-Freire A, Lashuel HA, Santos NC, Lopes LV, Xiang W, Jovin TM, Penque D, Engelender S, Zweckstetter M, Klucken J, Giorgini F, Quintas A, Outeiro TF (2017) Glycation potentiates \u03b1-synuclein-associated neurodegeneration in synucleinopathies. Brain J Neurol 140(1399):1419. https:\/\/doi.org\/10.1093\/brain\/awx056","journal-title":"Brain J Neurol"},{"key":"2297_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.coph.2013.06.009","volume":"13","author":"MS Ward","year":"2013","unstructured":"Ward MS, Fortheringham AK, Cooper ME, Forbes JM (2013) Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr Opin Pharmacol 13:654\u2013661. https:\/\/doi.org\/10.1016\/j.coph.2013.06.009","journal-title":"Curr Opin Pharmacol"},{"key":"2297_CR50","unstructured":"What is Alzheimer\u2019s disease? | CDC, https:\/\/www.cdc.gov\/aging\/aginginfo\/alzheimers.htm"},{"key":"2297_CR51","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell 186:693\u2013714. https:\/\/doi.org\/10.1016\/j.cell.2022.12.032","journal-title":"Cell"},{"key":"2297_CR52","doi-asserted-by":"publisher","first-page":"112548","DOI":"10.1016\/j.jep.2020.112548","volume":"251","author":"R Xiong","year":"2020","unstructured":"Xiong R, Wang X-L, Wu J-M, Tang Y, Qiu W-Q, Shen X, Teng J-F, Pan R, Zhao Y, Yu L, Liu J, Chen H-X, Qin D-L, Yu C-L, Wu A-G (2020) Polyphenols isolated from lychee seed inhibit Alzheimer\u2019s disease-associated tau through improving insulin resistance via the IRS-1\/PI3K\/Akt\/GSK-3\u03b2 pathway. J Ethnopharmacol 251:112548. https:\/\/doi.org\/10.1016\/j.jep.2020.112548","journal-title":"J Ethnopharmacol"},{"key":"2297_CR53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.str.2011.02.013","volume":"19","author":"J Xue","year":"2011","unstructured":"Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, Burz DS, Schmidt AM, Hoffmann R, Shekhtman A (2011) Advanced glycation end product recognition by the receptor for AGEs. Structure 19:722\u2013732. https:\/\/doi.org\/10.1016\/j.str.2011.02.013","journal-title":"Structure"},{"key":"2297_CR54","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.3390\/molecules27154922","volume":"27","author":"Q Yue","year":"2022","unstructured":"Yue Q, Song Y, Liu Z, Zhang L, Yang L, Li J (2022) Receptor for advanced glycation end products (RAGE): a pivotal hub in immune diseases. Mol Basel Switz 27:4922. https:\/\/doi.org\/10.3390\/molecules27154922","journal-title":"Mol Basel Switz"},{"key":"2297_CR55","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.1111\/ejn.15433","volume":"54","author":"K Zglejc-Waszak","year":"2021","unstructured":"Zglejc-Waszak K, Mukherjee K, Juranek JK (2021) The cross-talk between RAGE and DIAPH1 in neurological complications of diabetes: a review. Eur J Neurosci 54:5982\u20135999. https:\/\/doi.org\/10.1111\/ejn.15433","journal-title":"Eur J Neurosci"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-024-02297-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12031-024-02297-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-024-02297-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T23:39:44Z","timestamp":1735947584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12031-024-02297-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2297"],"URL":"https:\/\/doi.org\/10.1007\/s12031-024-02297-1","relation":{},"ISSN":["1559-1166"],"issn-type":[{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"114"}}